截止2022底有医护及科研人员531余人，其中正高级职称25人，副高级职称15人，博士生导师13人，硕士生导师7人。我所由造血干细胞移植病房、普通血液病房、门诊、临床诊断中心及诊治转化研发中心组成。临床诊断中心目前由流式细胞及分子生物学实验室，细胞遗传学实验室，HLA配型室，骨髓形态及病理实验室、细胞采集与细胞治疗室和移植免疫学实验室等组成。

       研究所致力于疑难重症血液病诊治，目前是我国最具国际影响力的血液病综合诊治中心之一，是引领国际的、全球最大的异基因干细胞移植中心。白血病、再障贫血和出凝血疾病等诊疗处于国际先进水平。我所以血液系统恶性肿瘤的诊断和治疗为主要研究方向，建立了三个核心平台，即“国际先进的血液病精准诊断平台”、“转化研发平台”以及引领国际的“干细胞移植综合治疗平台”。同时针对疑难血液病，利用核心公共平台，瞄准细胞和/或靶向治疗等的全球前沿，推广适宜技术、验证并规范诊疗新技术；致力原创成果的转化。

       研究所是国家血液系统疾病临床医学研究中心、国家重点学科、国家临床重点专科、科技部创新团队、教育部创新团队、基金委创新群体、国家药理基地、造血干细胞移植治疗血液病北京市重点实验室、细胞治疗北京市工程实验室，本中心与美国最大的癌症中心MD Anderson为全球前两大造血干细胞移植中心（本中心异基因病例数全球第一、总移植数第二）。包括院士1名、 “万人”领军人才1名、长江学者3名、“杰青”2名、“千人”2名、“青千”1名；是中华医学会血液学分会主委和中国医师协会血液学分会会长单位。近5年承担国家重点研发计划，863、973计划，国家科技重大专项等重大课题；获国家科技进步奖等多项奖励及授权专利。通讯/第一作者在N Engl J Med、J Clin Oncol和Blood等国际顶级期刊上发表一系列改变血液病诊治现状的临床研究成果；近5年位列“中国医院及专科声誉排行榜”综合医院血液科第一名，获“中国最佳临床学科评估排行榜”血液科第一名，“中国医院科技影响力排行榜” 综合医院血液科第一名。

       长期以来为全国最主要的造血干细胞移植规范化培训中心，通过全国会议、培训班、访问学者制度培训大夫万余人次。主持/参与60余项国内外多中心临床研究，改变/影响欧美指南/共识28项，主持制定我国指南/共识15项。

近年来的重要科研成果及贡献

       1.自创的粒细胞集落刺激因子（G-CSF）诱导免疫耐受的基础上，针对单倍型相合移植的多个方面，逐步建立并完善移植物抗宿主病防治、复发防治、供者选择、感染防治等多项关键技术，形成近年被国际公认的单倍型相合移植体系—“北京方案”。北京方案使单倍型相合移植疗效获显著提高。三年无病生存由20%上升到达70%,取得了和HLA配型相合移植一致的疗效,也优于单纯化疗；应用“北京方案”进行造血干细胞移植数目占据世界单倍型移植例数半壁江山，基本解决供者来源匮乏的世界性难题，迎来“人人都有供者”的新时代；

       2.在全球首次实现“基于口服药物的家庭式APL治疗模式”；

       3.改变了急性髓系白血病t（8;21）的“不需要造血干细胞移植”的治疗观念，研究被写入2017年ELN关于AML诊治的国际专家共识。

机构负责人：黄晓军

联系人:陈月

邮箱：bayou919@163.com

电话：010-88324577

地址：北京市西直门南大街11号

Peking University Institute of Hematology

National Clinical Research Center for Hematologic Disease

Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation

The department of Hematology was founded in 1957, and in 1981, Peking University Institute of Hematology was founded, which initiated hematopoietic stem cell transplantation in China. The institute now has 370 beds, including 81 beds of laminar flow ward, and the outpatient amounts go up to 14 billion people per year.

 

By the end of 2022, the institute had 531 staffs，including doctors, nurses and research scientists, among of which there were 25 senior positions,15 senior positions, 13 PhD tutors, 7 master instructors, respectively. The institute is constituted of the hematopoietic stem cell transplantation center, leukemia department, lymphoma and myeloma department, the outpatients section, the clinical diagnosis center, as well as the translational research center. The clinical diagnosis center consists of the flow cytometry and molecular biology laboratory, the cytogenetics laboratory, the HLA typing laboratory, the medullary morphology, the pathology laboratory, the stem cell collection and therapy laboratory and the transplantation immunology laboratory.

The institute has been committed to the diagnosis and treatment of difficult and critical hematological disease, and currently is one of the most internationally influential centers for comprehensive diagnosis and treatment of hematological disease in China, and also is the world's largest allogeneic stem cell transplantation center. The level of diagnosis and treatment of leukemia、aplastic anemia and the hemorrhage and coagulation diseases are at advance in the world. The institute includes three core platforms, they are “the national advanced precise diagnostic platform for hematologic diseases”, “the platform for the translational research” and “the comprehensive treatment platform for stem cell transplantation”, which is leading the world.

The institute is the National Clinical Research Center for Hematologic Disease, the State key discipline, the state clinical key discipline, the innovative Group of Ministry of Education, the innovative Group of the National Natural Science Foundation of China, the National pharmacological base, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation，Beijing Engineering Laboratory of Cell Therapy. The institute and MD Anderson Cancer Center are the two largest hematopoietic stem cell transplantation centers in the world (the number of allogeneic cases performed in our center is the first and the total number of transplantation is the second in the world). There are one academician, one leading academic for “Ten Thousand Talent Program”, three Changjiang scholar, and three “Distinguished Young Scholars”, one scholar enrolled “Thousand Talents Plan”, one scholar enrolled “Thousand Youth Talents Plan” in the institute. Prof. Huang is also the chairman of Hematology branch of the Chinese Medical Association and Hematology branch of Chinese Medical Doctor Association. In the recent 5 years, the institute has undertaken the national key research and development program, 863、973 program，and other national scientific and technological major project，and has won many awards and authorized patents, such as the National Science and Technology Progress Award. As the corresponding/ first author, we have published a series of clinical and translational studies in the top international journals, such as N Engl J Med，J Clin Oncol and Blood etc. In the recent five years, the institute has been ranked No. 1 in the General Hospital Hematology Department according to the “Chinese hospitals and specialist reputation rankings”, and also went to the top of Hematology Department in China's Best Clinical discipline Evaluation list, and General Hospital Hematology Department according to “China Hospital Science and Technology impact list”. Being the most important standardized training center for hematopoietic stem cell transplantation in China for a long time, more than ten thousand people have been trained through national conferences, training courses, visiting scholar’s system. The doctors in the institute have participated or been as principle investigators in more than 60 multi-center clinical studies at home and abroad, and taken charge of the formulation of 15 guidelines or consensus in China.

Important scientific research achievements and contributions in recent years:

On the basis of our original granulocyte colony stimulating factor (G-CSF) inducing immune tolerance, we have established and improved a serial of key technologies to form haploidentical transplantation system, which are also called “Beijing Protocol” by internationally experts, including the prevention and therapy strategies for graft-versus-host disease, relapse, infection as well as the donor selection criteria in haploidentical transplantation. The percentage of three-year disease free survival post “Beijing Protocol” goes up from 20% to 70%, achieved the comparable effect with HLA matched sibling transplantation, and more efficient than chemotherapy alone. The total number of hematopoietic stem cell transplantation performed by “Beijing Protocol” have accounted for half of the cases of haploidentical transplantation in the world,  and launched a new era of everyone has a donor. 2) We established the “Family therapy model of APL with oral drug” in the world for the first time. 3) The conception of therapy for acute myeloid leukemia with t(8;21) has been changed by our study, which screen out some kinds of patients need to perform stem cell transplantation for the first time. This research was cited by the international expert consensus on AML diagnosis and therapy in 2017 ELN.

 

Director: Xiaojun Huang

Contact: Yue Chen

E-mail: bayou919@163.com

Phone:86-10-88324577

Address: No 11 Xizhimen South Street, Beijing 100044, P. R. China.